News
For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
14th
Apr 21
Pharmaxis Sells Bronchitol Russian Distribution Rights for A$2m with Annual A$1m Cost Savings
Highlights:
- Pharmaxis sells distribution rights for Bronchitol in Russia effective May 1st 2021
- Pharmaxis to receive a €1.25 million (~A$2m) distributor appointment fee
- Annual cost savings of approximately A$1m realised from transfer of commercial and product responsibilities
14th
Apr 21
Pharmaxis Announces A$4.4m Placement
Highlights:
- A$4.4m being raised in a placement to institutional investors
- A$20m pro-forma cash balance post raising
- Strengthened balance sheet to support ongoing clinical studies in myelofibrosis and skin scarring
- Issue price of A$0.08 represents a 1.3% premium to last closing price as at 12 April 2021
- New shareholder Karst Peak Capital Limited invests A$3.2m for a 8.9% holding in the Company
- Existing shareholder BVF Partners LP invests A$0.8m to maintain its holding at 19.5%